My interaction, collaboration with and assessment of different biotech companies in the past 10+ years gives me a unique insight into their dynamics, goals, struggles, competitive arenas, and their likelihood to succeed. Therefore, my articles are based on hands-on experience and don’t rely merely on research of available written material out there in the cloud. I have studied during the last 20+ years intensively lethal virological and bacteriological pathogens and gained experience in rational vaccine design and the approval process for human and veterinarian vaccine candidates. I have been involved in many aspects of the biotechnology field (university, government, biotechnology companies) ranging from Basic Research and Development, Project/Program Management, Teaching, Business Development, Process Development, Manufacturing, Quality Assurance and Quality Control, Clinical Development, and Regulatory Affairs. Biotech, specifically start-up or early stage companies are high-risk investments, but with the right pick, proper due diligence and some luck a fantastic return can be achieved. In addition, due diligence gives a potential investor insight into potential world-changing therapeutics and prophylactic measures urgently needed in our health care system.